Pnd54 - A Long Term Analysis of the Clinical and Cost Effectiveness of Glatiramer Acetate Using Final 10-Year Results From the Uk Multiple Sclerosis Risk Sharing Scheme

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2020
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Assessing the Long-Term Effectiveness of Interferon-Beta and Glatiramer Acetate in Multiple Sclerosis: Final 10-Year Results From the UK Multiple Sclerosis Risk-Sharing Scheme

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2018English

A Long Term Analysis of the Clinical and Cost Effectiveness of Glatiramer Acetate From the Uk Multiple Sclerosis Risk Sharing Scheme

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Promoting Oligodendrogenesis and Myelin Repair Using the Multiple Sclerosis Medication Glatiramer Acetate

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2009English

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis

Journal of Central Nervous System Disease
2012English

Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2011English

UK Multiple Sclerosis Risk-Sharing Scheme: A New Natural History Dataset and an Improved Markov Model

BMJ Open
Medicine
2014English

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Sub-Analysis of Geographical Variations in the 2-Year Observational COPTIMIZE Trial of Patients With Relapsing–remitting Multiple Sclerosis Converting to Glatiramer Acetate

BMC Neurology
MedicineNeurology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy